RGS19抗体;RGS19 Antibody—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P13189(RGS19 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

The Regulator of G-protein Signaling 19 (RGS19), also known as GAIP (Gα-interacting protein), is a member of the RGS protein family that modulates G-protein-coupled receptor (GPCR) signaling. RGS19 acts as a GTPase-activating protein (GAP) for Gαi/o and Gαq subunits, accelerating GTP hydrolysis to terminate GPCR-mediated signal transduction. This regulatory function impacts diverse physiological processes, including immune responses, neurotransmission, and cell proliferation.

RGS19 is expressed in various tissues, with notable roles in the immune system and the central nervous system. Studies highlight its involvement in cancer progression, where dysregulated RGS19 expression has been linked to malignancies such as leukemia, breast cancer, and hepatocellular carcinoma. Its interaction with oncogenic pathways, such as the PI3K/AKT and MAPK cascades, suggests a potential role in tumorigenesis and metastasis.

RGS19-specific antibodies are critical tools for investigating its expression, localization, and mechanistic roles in both physiological and pathological contexts. These antibodies enable techniques like Western blotting, immunohistochemistry, and immunofluorescence, aiding in the study of RGS19's tissue distribution and interaction networks. Additionally, they support drug discovery efforts targeting RGS19-associated pathways, particularly in cancers and neurological disorders. Research using RGS19 antibodies may uncover therapeutic strategies to modulate GPCR signaling, offering avenues for precision medicine in diseases with aberrant RGS19 activity.